Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation

@inproceedings{Krijanovski2008DasatinibRI,
  title={Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation},
  author={Yelena Krijanovski and Nicholas J. Donato and Hanshi Sun and Feng Meng and Alfonso Quint{\'a}s-Cardama and Jorge E Cortes and Moshe Talpaz},
  year={2008}
}
Background Dasatinib is a multi–tyrosine kinase–specific inhibitor with potent inhibitory activity against bcrabl kinase. It has been increasingly used in the treatment of imatinib-resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia. However, despite its excellent activity, a proportion of patients present evidence of dasatinib resistance.